Literature DB >> 8580159

Measurement of brimonidine concentrations in human plasma by a highly sensitive gas chromatography/mass spectrometric assay.

A Acheampong1, D D Tang-Liu.   

Abstract

Brimonidine is an alpha 2-adrenergic agonist that is efficacious in lowering intraocular pressure in humans. A highly sensitive and selective gas chromatography/mass spectrometry (GC/MS) assay is described for quantitation of brimonidine in human plasma following ocular installation. Brimonidine in 1 ml of plasma was extracted together with tetradeuterated brimonidine (internal standard) and clonidine (carrier) by solvent extraction. After solvent evaporation, 3,5-bis(trifluoromethyl)benzoyl derivatives were formed and injected onto a GC/MS apparatus under negative chemical ionization conditions. The ions monitored for derivatized brimonidine and tetradeuterated brimonidine were m/z 691 [M-HBr] and m/z 694 [M-DBr], respectively. Calibration curves were linear from 2 to 1000 pg ml-1 (r2 = 0.981-0.996). The method was specific for brimonidine relative to endogenous compounds in plasma. The inter-day relative standard deviation for analysis of quality controls was 12% or less, and the inter-day assay accuracy ranged from 97 to 104% of nominals. The GC/MS assay showed adequate sensitivity for analysis of human samples from volunteers ocularly dosed with 0.5% brimonidine tartrate solution. Overall, the GC/MS assay showed excellent precision and accuracy, and a minimum quantifiable concentration of 2 pg ml-1.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8580159     DOI: 10.1016/0731-7085(95)01526-q

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  6 in total

Review 1.  Pharmacotherapy and Adherence Issues in Treating Elderly Patients with Glaucoma.

Authors:  David C Broadway; Heidi Cate
Journal:  Drugs Aging       Date:  2015-07       Impact factor: 3.923

Review 2.  Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension.

Authors:  J C Adkins; J A Balfour
Journal:  Drugs Aging       Date:  1998-03       Impact factor: 3.923

3.  A validated stability-indicating HPLC method for determination of brimonidine tartrate in BRI/PHEMA drug delivery systems.

Authors:  Jianguo Sun; Xiuwen Zhang; Taomin Huang
Journal:  Chem Cent J       Date:  2017-07-11       Impact factor: 4.215

4.  28-day intraocular pressure reduction with a single dose of brimonidine tartrate-loaded microspheres.

Authors:  Morgan V Fedorchak; Ian P Conner; Carlos A Medina; Jeremy B Wingard; Joel S Schuman; Steven R Little
Journal:  Exp Eye Res       Date:  2014-06-28       Impact factor: 3.467

5.  Fluorimetric quantification of brimonidine tartrate in eye drops.

Authors:  G Sunitha; R Bhagirath; V R Alapati; K Ramakrishna; C V S Subrahmanyam; P D Anumolu
Journal:  Indian J Pharm Sci       Date:  2013-11       Impact factor: 0.975

6.  Fast separation and quantification of three anti-glaucoma drugs by high-performance liquid chromatography UV detection.

Authors:  Mohamed Walash; Rania El-Shaheny
Journal:  J Food Drug Anal       Date:  2016-01-05       Impact factor: 6.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.